Welldoc, a leading digital health company, announced today an additional FDA-clearance for its BlueStar® digital health product.
The new enhancements include Continuous Glucose Monitoring (CGM) integration, as well as features to support individuals living with Type 1 diabetes.
This clearance demonstrates Welldoc’s commitment to providing BlueStar as a digital health product to support more people living with diabetes.
“With this clearance, we are very proud to bring BlueStar to support people living with Type 1 diabetes,” said Welldoc chief medical officer Dr. Mansur Shomali. “People with Type 1 diabetes have unique challenges and needs. They have to manage glucose, food, insulin, and physical activity throughout their hectic daily schedules.
Shomali said people can now use BlueStar to simplify some of their diabetes-related tasks such as calculating carbs, dosing insulin, and connecting to their favorite devices.
BlueStar’s insulin-dosing support has been further enhanced with the addition of insulin on board (IOB) feature, which helps minimize the risk of hypoglycemia. In addition, BlueStar users will be able to view and learn from their Dexcom CGM data.
Users will receive integrated insights regarding how their food choices, medications, and activity affect their glucose patterns. Healthcare providers will also be able to receive their patient’s CGM data, along with self-management data to make more effective adjustments to the treatment plan.
Type 1 diabetes affects approximately 1.25 million Americans and adds a significant burden to patients, their families, and the healthcare system.
This form of diabetes occurs when little and no insulin is produced by the pancreas, requiring constant attention to glucose, food, and insulin in order to stay well.
- WellDoc Inc. (2019, Nov 15). Welldoc’s Award-winning Digital Health Solution BlueStar Adds FDA-Clearance for Use in Type 1 Diabetes. PR Newswire. Retrieved Nov. 15, 2019, from https://prnmedia.prnewswire.com/news-releases/welldocs-award-winning-digital-health-solution-bluestar-adds-fda-clearance-for-use-in-type-1-diabetes-300951083.html